A Phase 3, Randomized, Open-label, Multicenter Study of Sacituzumab Tirumotecan (sac-TMT, MK-2870) Maintenance Treatment With or Without Bevacizumab Versus Standard of Care in Participants With Newly Diagnosed Advanced HRD-Negative Ovarian Cancer Following First-line Platinum-based Chemotherapy (TroFuse-021/ENGOTov85/ GOG-3102)

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-508047-40-00

Enrollment

283

Registered

2026-04-28

Start date

Unknown

Completion date

Unknown

Last updated

2026-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian cancer

Brief summary

Progression-Free Survival (PFS)

Detailed description

Overall Survival (OS), Second Progression-Free Survival (PFS2), Number of Participants Who Experience an Adverse Event (AE), Number of Participants Who Discontinue Study Treatment Due to an AE, Change From Baseline in Global Health Status/Quality of Life (GHS/QoL) Combined Score (Items 29 and 30) Using the European Organisation for Research and Treatment of Cancer QoL Questionnaire-Core 30 (EORTC QLQ-C30), Change From Baseline in Physical Functioning Combined Score (Items 1 to 5) Using EORTC QLQ-C30, Change From Baseline in Role Functioning Combined Score (Items 6 and 7) Using EORTC QLQ-C30, Change From Baseline in Abdominal/Gastrointestinal (GI) Symptoms Combined Score (Items 31 to 36) Using the EORTC QLQ-Ovarian Cancer Module 28 (OV28)

Interventions

DRUGMK-2870

DRUGAvastin 25 mg/ml concentrate for solution for infusion.

DRUG-

DRUGMVASI 25 mg/mL concentrate for solution for infusion

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Progression-Free Survival (PFS)	—

Secondary

Measure	Time frame
Overall Survival (OS), Second Progression-Free Survival (PFS2), Number of Participants Who Experience an Adverse Event (AE), Number of Participants Who Discontinue Study Treatment Due to an AE, Change From Baseline in Global Health Status/Quality of Life (GHS/QoL) Combined Score (Items 29 and 30) Using the European Organisation for Research and Treatment of Cancer QoL Questionnaire-Core 30 (EORTC QLQ-C30), Change From Baseline in Physical Functioning Combined Score (Items 1 to 5) Using EORTC QLQ-C30, Change From Baseline in Role Functioning Combined Score (Items 6 and 7) Using EORTC QLQ-C30, Change From Baseline in Abdominal/Gastrointestinal (GI) Symptoms Combined Score (Items 31 to 36) Using the EORTC QLQ-Ovarian Cancer Module 28 (OV28)	—

Measure

Time frame

—

Outcome results

None listed

Source: EU CTIS · Data processed: Apr 30, 2026